Web Results

curia.europa.eu/juris/liste.jsf?num=C-567/14&language=en

Judgment of the Court (First Chamber) of 7 July 2016. Genentech Inc. v Hoechst GmbH and Sanofi-Aventis Deutschland GmbH. Request for a preliminary ruling from the Cour d'appel de Paris. Reference for a preliminary ruling — Competition — Article 101 TFEU — Non-exclusive licence agreement — Patent — No ...

caselaw.findlaw.com/us-federal-circuit/1630869.html

May 10, 2013 ... Case opinion for US Federal Circuit SANOFI AVENTIS DEUTSCHLAND GMBH v. Biogen Idec Inc., Defendant.. Read the Court's full decision on FindLaw.

www.ncbi.nlm.nih.gov/pmc/articles/PMC4733135

Jan 12, 2016 ... Teriflunomide is the active metabolite of leflunomide (ARAVA®, Sanofi-Aventis Deutschland GmbH, Germany), a disease-modifying antirheumatic drug ... endpoint) by 31.5 % (p < 0.001) and reduced the risk of disability progression ( key secondary endpoint) by 30.0 % (p < 0.05) versus placebo (Table 2).